Australia’s Billion-Dollar Cannabis Milestone: 41 Cultivators, 41 Tonnes, and a Market That Won’t Stop Growing

How did Australia go from zero licensed cannabis cultivators in 2016 to a billion-dollar medical cannabis market with 41 licensed growers, 41 tonnes of annual production, and over half a million patient approvals?

Australia’s medical cannabis market crossed the AUD $1 billion mark in 2025. That single figure captures a transformation that has unfolded with remarkable speed: from a market that did not exist a decade ago to one that now supports 41 TGA-licensed cultivators, 27 licensed manufacturers, 35 licensed importers, and an estimated 41 tonnes of domestic cannabis production in 2024. The Therapeutic Goods Administration’s Special Access Scheme has processed over 500,000 individual patient approvals since its inception, and monthly prescription volumes continue to climb.

For an island nation of 26 million people separated from major cannabis-producing regions by thousands of kilometres of ocean, Australia has built something that few predicted: a sophisticated, heavily regulated, and increasingly self-sufficient medical cannabis ecosystem. But the market’s trajectory is not without tension. Import dependency remains high despite growing domestic production. Pricing pressure from Canadian and European competitors is compressing margins. Discussions about tariffs on imported cannabis have intensified. And the regulatory burden of TGA compliance — among the most demanding pharmaceutical frameworks in the world — continues to challenge smaller operators.

This article examines the full picture of Australia’s cannabis market as of early 2026: the production data, the patient access numbers, the regulatory architecture, the export ambitions, and the compliance infrastructure that operators need to compete in what has become one of the most consequential medical cannabis markets outside of North America and Europe.

The Numbers: Australia’s Cannabis Market From 2019 to 2025

Australia’s medical cannabis market has experienced compounding growth since the first Special Access Scheme — Category B (SAS-B) approvals were granted for cannabis products. The trajectory from a nascent pilot programme to a billion-dollar industry spans just six years, with each year bringing structural milestones that expanded both the supply side and the patient base.

Sources: Therapeutic Goods Administration (TGA) reporting, Office of Drug Control (ODC) data, Freshleaf Analytics, Prohibition Partners Asia-Pacific

The growth rate has moderated from the explosive 150-160% annual increases of 2020-2021 to a still-robust 20-25% in 2024-2025. This deceleration reflects market maturation rather than weakening demand: the patient base continues to expand, but the early surge driven by telehealth adoption and pandemic-era regulatory flexibility has transitioned into steadier, structurally driven growth.

In revenue terms, the AUD $1 billion milestone places Australia among the top five medical cannabis markets globally, behind Germany, Canada’s domestic medical market, and the United States (where state-level medical programmes collectively dwarf all others). Within the Asia-Pacific region, Australia is the dominant market by a wide margin — no other country in the region approaches its scale, patient access, or regulatory maturity.

Patient Access: The TGA Special Access Scheme and Prescription Volumes

The foundation of Australia’s medical cannabis market is the Therapeutic Goods Administration’s Special Access Scheme, specifically the Category B (SAS-B) pathway that enables authorised prescribers to request approval for unapproved therapeutic goods on a patient-by-patient basis. Understanding how this system works — and how it has evolved — is essential for anyone analysing the Australian market.

How the SAS-B Pathway Works

Under SAS-B, a medical practitioner must apply to the TGA for approval to prescribe a specific cannabis product to a specific patient. The application requires clinical justification, patient consent, and evidence that conventional treatments have been inadequate. Once approved, the prescriber can issue a prescription that is filled through an authorised pharmacy.

The process was historically cumbersome. Early SAS-B applications could take weeks to process, and the administrative burden deterred many general practitioners from prescribing. Beginning in 2020, the TGA implemented significant reforms:

• Online portal: A streamlined digital application system reduced processing times from weeks to days, and in many cases to under 48 hours
• Authorised Prescriber scheme: Clinicians who demonstrate expertise and apply successfully can become Authorised Prescribers (APs), enabling them to prescribe specific cannabis products to classes of patients without individual SAS-B applications
• Telehealth integration: COVID-era telehealth provisions were extended, allowing initial and follow-up consultations to occur remotely — a critical enabler of patient access in a geographically vast country

Patient Approval Volumes

The cumulative impact of these reforms is visible in the approval data. The TGA has processed over 530,000 SAS-B approvals for cannabis products through early 2026, with monthly approval volumes now consistently exceeding 20,000.

Sources: TGA SAS-B quarterly reports, ODC data

The number of Authorised Prescribers has grown from fewer than 100 in 2019 to over 1,700 in 2025, reflecting growing clinical confidence and familiarity with cannabis prescribing. However, prescriber concentration remains a feature of the market — a relatively small cohort of high-volume prescribers, often associated with specialist cannabis clinics, accounts for a disproportionate share of approvals.

Prescribing Conditions

The TGA does not maintain a restrictive list of qualifying conditions for medical cannabis. The SAS-B pathway is indication-agnostic — any condition can qualify if the prescriber provides adequate clinical justification. In practice, the primary prescribing indications mirror those seen in other mature medical cannabis markets:

• Chronic pain — The single largest category, encompassing neuropathic pain, musculoskeletal conditions, fibromyalgia, and treatment-resistant pain syndromes
• Anxiety disorders — Including generalised anxiety disorder, social anxiety, and PTSD
• Insomnia and sleep disorders — A rapidly growing category
• Cancer-related symptoms — Pain, nausea, and appetite stimulation
• Neurological conditions — Epilepsy, multiple sclerosis, and Parkinson’s disease
• Palliative care — End-of-life symptom management

The Production Landscape: 41 Cultivators, 27 Manufacturers, 35 Importers

Australia’s cannabis supply chain has matured significantly since the first cultivation licences were issued under the Narcotic Drugs Act 1967 (amended 2016). The Office of Drug Control (ODC), operating within the Department of Health and Aged Care, oversees the licensing framework that now encompasses three distinct licence categories.

Licence Categories and Counts (as of late 2025)

Source: Office of Drug Control (ODC) licence register

Domestic Production Growth

The 41 tonnes of cannabis produced domestically in 2024 represents a remarkable scaling achievement. Australian production has roughly doubled each year since 2020, driven by:

• Facility expansion: Early licence holders have progressively expanded cultivation capacity, moving from pilot-scale operations to commercial indoor and greenhouse facilities
• New entrants: The number of licensed cultivators grew from 12 in 2019 to 41 in 2025, with new entrants ranging from Australian-founded companies to subsidiaries of international cannabis firms
• Improved yields: As operators gain experience with Australian growing conditions and TGA-compliant cultivation protocols, per-plant and per-square-metre yields have improved
• Product diversification: Demand for domestically produced cannabis flower, oils, and extracts has expanded as patients and prescribers become more comfortable with Australian-grown products

Key Domestic Producers

Several companies have emerged as significant players in Australia’s domestic production landscape:

• Cannatrek — One of Australia’s largest vertically integrated cannabis companies, operating cultivation, manufacturing, and distribution facilities in Victoria and Queensland
• Little Green Pharma (LGP) — A Perth-based cultivator and manufacturer that was among the first Australian companies to achieve commercial-scale production and export capability
• Levin Health — Operating GMP-certified facilities focused on pharmaceutical-grade cannabis production
• Althea Group (Peak Processing) — A Melbourne-based company with cultivation and processing operations, plus significant international partnerships
• ECS Botanics — A Tasmanian cultivator that has scaled outdoor and greenhouse production

The competitive dynamics among domestic producers are intensifying. With 41 licensed cultivators competing for a domestic market that, while growing, absorbs only a portion of national production capacity, consolidation pressures are building. Smaller operators without manufacturing capabilities or established distribution relationships face particular challenges.

Import Dependency vs. Domestic Production: A Market in Transition

Despite the growth of domestic production, Australia remains substantially dependent on imports — particularly from Canada — to meet patient demand. Understanding this dynamic is critical for operators and investors evaluating the market’s trajectory.

The Import Picture

Australia imported an estimated 60-65 tonnes of medical cannabis products in 2024, compared to the 41 tonnes produced domestically. Canadian licensed producers have been the dominant import source, supplying an estimated 70-75% of imported volume, with the remainder coming from Europe (primarily the Netherlands, Denmark, and Germany) and Israel.

The cumulative value of Canadian cannabis exports to Australia between January 2024 and early 2026 reached approximately CA$230 million — making Australia Canada’s second-largest flower export destination by value after Germany.

Note: Volumes are estimates based on ODC import data, Health Canada export permits, and industry reporting. Total includes all product forms converted to dried flower equivalent.

The Tariff Discussion

One of the most significant policy debates in Australia’s cannabis market concerns the potential introduction of tariffs on imported cannabis — particularly from Canada. Discussions have intensified through 2025 as domestic producers argue that Canadian imports, benefiting from Canada’s massive production overcapacity and compressed domestic pricing, are entering the Australian market at prices that undercut local growers.

The arguments on both sides are substantial:

Pro-tariff (domestic producer perspective):

• Australian cultivators invested heavily in TGA-compliant facilities and deserve protection from below-cost imports
• Domestic production supports Australian jobs and reduces supply chain vulnerability
• Canadian export prices reflect domestic oversupply conditions, not true production costs

Anti-tariff (importer and patient advocate perspective):

• Tariffs would increase patient costs in a market where out-of-pocket expenses are already significant
• Import competition drives quality improvement and product diversity
• Restricting supply could create shortages for specific product categories not yet produced domestically

As of early 2026, no formal tariff mechanism has been implemented, but the debate continues to shape policy discussions within the Department of Health and the ODC.

Market Segments: What Australian Patients Are Using

The composition of Australia’s medical cannabis market reflects both patient preferences and the evolving product landscape. Unlike some emerging markets where product diversity is limited, Australia’s market now encompasses a broad range of dosage forms.

Product Category Breakdown (2025 estimated)

Dried flower dominance is a consistent pattern across mature medical cannabis markets — Germany, the UK, and Canada all show similar category distributions. For Australian producers and importers, the implication is clear: flower quality, strain diversity, and competitive pricing on dried flower products are the primary competitive battleground.

Pricing Dynamics

Australian medical cannabis pricing has experienced significant compression since the market’s early years, though prices remain higher than in Canada’s domestic market or Germany’s increasingly competitive import market.

Price compression has been driven by increased competition among importers and domestic producers, patient demand for affordability, and the entry of lower-cost Canadian product into the market. For operators, this means that production efficiency, supply chain optimisation, and regulatory compliance cost management are becoming critical differentiators.

Export Ambitions: Australia Targets International Markets

One of the most significant developments in Australia’s cannabis market is the emergence of export activity. While Australia has historically been a net importer, a growing number of licensed producers are now targeting international markets — with Germany as the primary destination.

Australia’s Export Data

In 2025, Australian cannabis companies shipped an estimated 4,190 kg to Germany — more than triple the volume exported in 2024. While this figure is modest compared to Canada’s 93,006 kg to Germany in the same period, the growth trajectory signals serious intent.

Sources: BfArM German import data, industry reporting

Why Australia Can Compete in Export Markets

Australia’s export proposition rests on several advantages:

1. TGA and TGO 93 compliance: Products manufactured to TGA standards, including Therapeutic Goods Order No. 93 (TGO 93) specifications for medicinal cannabis, meet or exceed EU-GMP requirements in many respects. The rigorous Australian regulatory framework provides a quality assurance signal that international buyers value.

2. Southern Hemisphere growing season: Australia’s counter-seasonal harvest cycle means fresh product reaches Northern Hemisphere markets during their winter and spring months, when domestic European production is at seasonal lows.

3. Clean agricultural environment: Australia’s biosecurity standards and agricultural reputation provide a marketing advantage in markets where product provenance matters.

4. Established pharmaceutical infrastructure: Australia’s broader pharmaceutical manufacturing sector provides the quality systems, laboratory services, and regulatory expertise that cannabis companies need to achieve export-grade production.

Export Challenges

Despite these advantages, Australian exporters face significant headwinds:

• Distance and logistics costs: Shipping cannabis from Australia to Europe involves longer transit times and higher freight costs compared to Canadian or Portuguese competitors
• Scale disadvantage: Australian production volumes remain a fraction of Canada’s capacity, limiting the ability to compete on price
• Regulatory complexity: Export permits require coordination between the ODC, the TGA, and the importing country’s competent authority — a process that adds time and compliance cost to every shipment
• Currency exposure: The AUD/EUR exchange rate introduces margin volatility for exporters targeting European markets

The Regulatory Framework: TGA, ODC, and TGO 93

Australia’s cannabis regulatory framework is among the most comprehensive in the world, reflecting the country’s broader approach to therapeutic goods regulation. Operators must navigate multiple regulatory bodies and compliance standards simultaneously.

Key Regulatory Bodies

Therapeutic Goods Administration (TGA): The primary regulator for all therapeutic goods in Australia, including medical cannabis products. The TGA oversees product quality standards, the SAS-B approval pathway, the Authorised Prescriber scheme, and adverse event reporting.

Office of Drug Control (ODC): Administers the licensing framework for cannabis cultivation, manufacturing, and importation under the Narcotic Drugs Act 1967. The ODC conducts facility inspections, issues and renews licences, and monitors compliance with licence conditions.

State and territory health departments: Some jurisdictions maintain additional approval requirements for cannabis prescriptions, though the trend has been toward harmonisation with the federal framework.

TGO 93: Australia’s Cannabis Quality Standard

Therapeutic Goods Order No. 93 (TGO 93) establishes the quality standards that medicinal cannabis products must meet for supply in Australia. TGO 93 specifies requirements across the full production chain:

• Identity and purity testing: Cannabinoid content (THC, CBD, and other specified cannabinoids) must be within declared ranges
• Contaminant limits: Maximum allowable levels for pesticides, heavy metals (arsenic, cadmium, lead, mercury), microbial contamination (total aerobic count, yeast, mould, E. coli, Salmonella, bile-tolerant gram-negative bacteria), and aflatoxins
• Stability testing: Products must demonstrate stability over their declared shelf life under specified storage conditions
• Labelling and packaging: Strict requirements for product labelling, including cannabinoid content declarations, batch numbers, expiry dates, and storage instructions
• Manufacturing standards: Production must occur in facilities operating under GMP standards appropriate to the product type

For international producers exporting to Australia, TGO 93 compliance is non-negotiable. Products that meet EU-GMP standards generally satisfy many TGO 93 requirements, but specific testing protocols and documentation formats may differ — requiring careful attention to Australian-specific compliance details.

Compliance Costs and Operational Impact

The cumulative compliance burden of operating within the TGA/ODC framework is substantial. Industry estimates suggest that regulatory compliance costs account for 15-25% of total operating costs for Australian cannabis companies — significantly higher than in less regulated markets. These costs include:

• Annual licence fees and renewal processes
• Facility audits and inspection preparation
• Quality testing programmes (in-house and third-party laboratory)
• Regulatory affairs personnel and external consultants
• Documentation systems for batch records, SOPs, and deviation tracking
• Adverse event reporting and pharmacovigilance obligations

For smaller operators, these compliance costs create a meaningful barrier to market entry and ongoing profitability. The result is a market that increasingly favours well-capitalised companies with established quality management systems and regulatory expertise.

Challenges Facing the Australian Cannabis Market

While the growth trajectory is compelling, Australia’s cannabis market faces several structural challenges that will shape its evolution through 2026 and beyond.

Pricing Pressure and Margin Compression

The combination of growing domestic production, sustained import volumes, and increasing patient expectations for affordability is compressing margins across the supply chain. Dried flower wholesale prices have declined approximately 30-35% since 2021, and further compression is expected as competition intensifies. For operators without scale advantages or differentiated product portfolios, margin pressure threatens viability.

Import Competition and the Canadian Factor

Canada’s massive production overcapacity — licensed producers hold hundreds of tonnes of unsold domestic inventory — means that Canadian cannabis enters the Australian market at prices that reflect compressed Canadian domestic economics rather than true production costs. Australian domestic producers argue this creates an unlevel playing field, particularly when Canadian wholesale prices can be CA$1-3 per gram compared to Australian production costs of AUD $4-8 per gram.

Regulatory Complexity and Cost

The TGA/ODC framework, while providing robust patient safety protections, imposes compliance costs that are disproportionately burdensome for smaller operators. The requirement for individual SAS-B approvals (outside the Authorised Prescriber scheme) adds administrative overhead that does not exist in markets with simpler prescribing frameworks like Germany’s post-CanG system.

Geographic Challenges

Australia’s vast geography creates distribution challenges that do not exist in more compact markets. Ensuring consistent product availability in regional and remote areas — where patient populations may be dispersed across enormous distances — requires logistics infrastructure that adds cost and complexity.

Research Limitations

Despite having one of the world’s most active medical cannabis patient populations, Australia’s clinical research output has not kept pace. The disconnect between patient access (which has scaled rapidly) and evidence generation (which remains constrained by funding, institutional caution, and regulatory complexity around research licences) limits the market’s ability to build the clinical evidence base that would support further regulatory liberalisation.

How GrowerIQ Supports TGA Compliance and Cannabis Operations in Australia

The regulatory and compliance demands of operating in Australia’s medical cannabis market — TGA product standards, ODC licence conditions, TGO 93 quality requirements, batch-level traceability, and cross-border export documentation — represent a significant operational challenge. Manual compliance systems that function at small scale become unsustainable as production volumes grow and regulatory expectations intensify.

GrowerIQ’s seed-to-sale platform addresses the specific compliance requirements that Australian cannabis operators face:

TGO 93-Aligned Batch Documentation

Every cultivation batch tracked through GrowerIQ generates the documentation that TGO 93 and TGA inspections require — from seed or clone source records through cultivation environment data, harvest records, drying and curing conditions, processing steps, and quality testing results. Digital batch records eliminate the manual documentation gaps that are among the most common findings in ODC facility audits.

Integrated Quality Management System

GrowerIQ is the only cannabis seed-to-sale platform with a fully integrated Quality Management System (QMS) independently validated to meet GMP and PIC/S standards. For Australian operators holding manufacturing licences, this means deviation tracking, CAPA (Corrective and Preventive Action) management, and SOP compliance monitoring are built into the same platform that tracks production — not bolted on as a separate system.

Export Documentation and Lot Traceability

For Australian producers building export programmes to Germany and other international markets, GrowerIQ maintains the lot-level traceability data that importing country regulators require. Each export shipment can be traced back through the complete production chain, with documentation packages generated to satisfy both Australian export permit requirements and destination country import standards.

Automated Regulatory Reporting

The TGA’s reporting requirements — including adverse event data, product quality notifications, and periodic safety updates — can be generated from data already captured within the GrowerIQ platform, reducing the manual burden on regulatory affairs teams and minimising the risk of reporting errors.

COGS and Business Analytics

As Australian cannabis margins compress, understanding true cost-of-goods-sold at the batch level becomes critical for operational decision-making. GrowerIQ’s business analytics module tracks input costs, labour, testing expenses, and facility overhead against production output — enabling operators to identify which cultivars, production methods, and product categories deliver the best margins in an increasingly competitive market.

Frequently Asked Questions

How many licensed cannabis cultivators are there in Australia?

As of late 2025, the Office of Drug Control (ODC) has issued cannabis cultivation licences to 41 entities. These range from large-scale indoor and greenhouse operations to smaller boutique cultivators. The number has grown steadily from 12 in 2019 as the market has matured and demand has expanded. In addition, there are 27 licensed manufacturers and 35 licensed importers operating within the regulatory framework.

How do patients access medical cannabis in Australia?

Patients access medical cannabis through two primary TGA pathways. The Special Access Scheme — Category B (SAS-B) requires a prescribing doctor to apply to the TGA for approval for each patient. The Authorised Prescriber (AP) pathway allows approved clinicians to prescribe specific cannabis products to classes of patients without individual TGA applications. Over 1,700 clinicians held AP status by mid-2025. Both general practitioners and specialists can prescribe medical cannabis, and telehealth consultations are permitted for both initial and follow-up appointments.

Is Australia a net importer or exporter of cannabis?

Australia remains a net importer as of early 2026. Domestic production reached approximately 41 tonnes in 2024, while imports were estimated at 60-65 tonnes — meaning roughly 60% of Australia’s medical cannabis supply comes from international sources, primarily Canada. However, the balance is shifting as domestic production scales, and Australia has begun building export activity, shipping an estimated 4,190 kg to Germany in 2025.

What is TGO 93 and why does it matter for cannabis producers?

Therapeutic Goods Order No. 93 (TGO 93) is the TGA’s quality standard for medicinal cannabis products supplied in Australia. It specifies mandatory requirements for cannabinoid content accuracy, contaminant limits (pesticides, heavy metals, microbial), stability testing, labelling, and manufacturing standards. Compliance with TGO 93 is a legal requirement for all cannabis products entering the Australian market — whether produced domestically or imported. For international producers exporting to Australia, understanding the specific requirements of TGO 93 (which may differ from EU-GMP in certain testing protocols and documentation formats) is essential to market access.

This analysis is current as of April 2026 and draws on data from the Therapeutic Goods Administration (TGA), Office of Drug Control (ODC), German Federal Institute for Drugs and Medical Devices (BfArM), Health Canada export data, Freshleaf Analytics, Prohibition Partners, and industry reporting. Production and market value estimates reflect the best available data as of the publication date; official ODC figures for calendar year 2025 production are expected in mid-2026.

Sources:

• TGA Special Access Scheme — Category B statistics
• Office of Drug Control — Cannabis Licence Holders
• Freshleaf Analytics — Australian Medicinal Cannabis Market Quarterly Report 2025
• Prohibition Partners — Asia-Pacific Cannabis Report 2025
• BfArM — German Cannabis Import Data 2025
• Health Canada — International Cannabis Trade Data
• StratCann — Canadian Cannabis Exports Analysis 2025
• Cannatrek — Australian Medical Cannabis Market Overview
• Therapeutic Goods Order No. 93 — Standard for Medicinal Cannabis
• Little Green Pharma — Export Activities and International Market Data
• MJBizDaily — Australia Cannabis Market Reports